Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib as second-line therapy in NSCLC (SELINE)
NCT00608868Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gefitinib in non-small cell lung carcinoma (NSCLC), sponsored by AstraZeneca. Primary endpoint: Objective Response Rate at 8 weeks. Started Jan 2007; status: completed.
02
Drugs
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT00608868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00608868.